Grey Matters Health (GREY) AI Stock Analysis

• Market Cap: C$3.39M
• Dividend Yield: N/A
• Average Volume (3M): 9.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: N/A
• EPS Growth: 17.84%
• Country: CA
• Employees: 5
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.62
• Shares Outstanding: 8,923,237
• 10 Day Avg. Volume: 17,877
• 30 Day Avg. Volume: 9,966
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 5.02
• Revenue Forecast (FY): C$45.78M

• Rating: 41 Neutral
• Price Target: C$0.36 ▼(-19.33% Downside)
• Action: Reiterated
• Date: 10/03/26

Positive Factors

Debt-free balance sheet

No debt reduces interest expense and near-term repayment pressure, preserving financial flexibility while the company develops its VR healthcare and wellness offerings. This provides a stronger base for funding operations than a similarly loss-making business carrying material leverage.

Negative Factors

No demonstrated revenue base

Zero reported revenue means the business has not yet demonstrated commercial traction or a repeatable monetization engine for its VR applications. Without revenue scale, future growth remains dependent on converting healthcare and wellness offerings into paying demand.

Grey Matters Health Business Overview & Revenue Model

Company Description

Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney ...

Read more

Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney ...

Grey Matters Health Financial Statement Overview

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Grey Matters Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GREY, the sentiment is Negative. The current price of 0.45 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.45, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.17 is Neutral, neither overbought nor oversold. The STOCH value of 10.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GREY.

Grey Matters Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
GREY	41 Neutral	C$3.39M	-0.08	-92.73%	―	―	17.84%
APLI	41 Neutral	C$661.83K	-0.14	27.40%	―	249.12%	-93.09%